Finançament
- Immune cell communications in health and disease SGR 2021SGR00863 funded by AGENCIA DE GESTIO AJUTS UNIVERSITARIS DE RECERCA. Coordinator: A Ceruti, PI: Cristina López-Rodríguez, José Aramburu, Miguel López-Botet, Aura Muntasell.
- Optimizing NK cell-based immunotherapy in HER2+ breast cancer. FIS Project PI22/00040, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. PI: Aura Muntasell. Dates: 01/01/23-31/12/2025
- Phase Ib to evaluate safety of TAR-NK cells+cetuximab+irinotecan rechallenge in patients with mCRC (CITRIC-NK). CI24/00041 Proyectos de Investigación Clínica Independiente (ICI) funded by funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. PI: Clara Montagut and Aura Muntasell. Dates: 01/01/25-31/12/2028
- Dual genetic engineering of NK cells for cancer immunotherapy (DUAL-NK). Consolidación Investigadora funded by Ministerio de Ciencia e Innovación and co-funded by European Union. PI: Aura Muntasell. Dates 04/2024-04/2026
- Development of a TGF-β- and Activin A-Resistant off-the-shelf NK cell product for cancer treatment. 2024PROD00086, funded by Indústria del Coneixement Program, AGENCIA DE GESTIO AJUTS UNIVERSITARIS DE RECERCA AGAUR. PI: Aura Muntasell. Dates 01/12/2024-30/06/2026
